Lyra Therapeutics, Inc.

NASDAQ: LYRA · Healthcare · Biotechnology

PublicHQ Watertown, MACIK 0001327273Reports USD

#947 of 1,402 Healthcare companies by revenuebottom-quartile growth

EA Score

22D

FH 21DQ —GM 18SS 35

v0.1 · 45/100 weight · provisional

↑ workforce scale, return on assets · ↓ operating margin, net margin

Methodology →

Revenue TTM

$398.0k

Rev growth YoY (TTM)

needs 8 qtrs

Net income (FY)

-$28.9M

Employees

Market cap

$851.9k

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Revenue$398.0k$398.0k2025

Net income-$28.9M-$28.9M2025

Operating income-$31.0M-$31.0M2025

Total assets$36.1M$36.1M2025

Liabilities$46.8M$46.8M2025

Equity-$10.7M-$10.7M2025

Revenue trend

FY2021 – FY2025 · USD

$285.0k

FY21

$1.4M

FY22

$1.6M

FY23

$1.5M

FY24

$398.0k

FY25

Revenue by segment

No segmentation disclosed for this filer. n/a

The read

Lyra Therapeutics, Inc. booked $398.0k in FY2025 revenue, contracting 74% year over year — slower than 87% of Healthcare companies we track, at a -7266.1% net margin.

Peers · Healthcare

Catheter Precision, Inc.40D RushNet, Inc.——Enveric Biosciences, Inc.31D Mitesco, Inc.38D

Key facts

CEOCarmichael S. Roberts Jr.

SectorHealthcare

IndustryBiotechnology

HeadquartersWatertown, MA

ExchangeNASDAQ: LYRA

Employees30

IPO date2020-05-01

Latest filings

No filings loaded.

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.